Head-To-Head Review: Curis (CRIS) & Its Peers
Curis (NASDAQ: CRIS) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Curis to similar businesses based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
This is a summary of recent ratings and recommmendations for Curis and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Curis currently has a consensus target price of $6.50, suggesting a potential upside of 311.39%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.38%. Given Curis’ stronger consensus rating and higher possible upside, research analysts clearly believe Curis is more favorable than its rivals.
Insider and Institutional Ownership
44.7% of Curis shares are owned by institutional investors. Comparatively, 48.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 4.1% of Curis shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Curis and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Curis has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Curis’ rivals have a beta of 1.63, suggesting that their average stock price is 63% more volatile than the S&P 500.
Earnings and Valuation
This table compares Curis and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Curis||$8.31 million||-$48.51 million||-3.16|
|Curis Competitors||$206.18 million||-$2.14 million||2.43|
Curis’ rivals have higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Curis rivals beat Curis on 7 of the 12 factors compared.
Curis Company Profile
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.